MedCannID insights from 1000 UK medical cannabis prescriptions

The number of patients in the UK exploring the option of medical cannabis on prescription continues to grow. Current estimates suggest that perhaps 6000 patients have been prescribed medical cannabis for a range of conditions in the UK, up from about 2000 at the turn...

Addressing ESG issues in the medicinal cannabis industry

As part of research at the University of Cambridge Institute for Sustainability Leadership, we developed and sent out a survey to a hundred key stakeholders in the global medicinal cannabis industry. Participating stakeholders were chosen from our network due to their...
ACMD assess impact of rescheduling. What can we learn?

ACMD assess impact of rescheduling. What can we learn?

Two years after the Advisory Council on the Misuse of Drugs (ACMD) recommended that Cannabis Based Products for Medicinal use (CBPM) be moved into Schedule 2 under the Misuse of Drugs Regulations 2001 (MDR), the ACMD reflect and assess the impact of this important...
Sustainability & Alta Flora

Sustainability & Alta Flora

An intro to sustainability at Alta Flora Sustainability means different things to different people; it is a concept with a wide range of interpretations that are often easily confused. Should you want to familiarise yourself, our friend André Gonçalves at Youmatter...
Two years on – what does the data say?

Two years on – what does the data say?

Two years ago yesterday we saw the then Home Secretary Savid Javid, under significant public pressure, take the first step towards undoing decades of regressive policies towards medical cannabis and the patients that rely on it. The cases of Billy Cauldwell and Alfie...
Introducing Eva

Introducing Eva

Just over 4 years ago, I wrote a piece in the Huffington Post titled “Medical Cannabis Can Make A Real Difference To People’s Suffering – Let’s Free Its Potential”. In the piece, I argued that the Barnes Report of 2016 marked a turning point in UK...